2nd Quarter - Report
IKARIA for IKARIA
Firm
Client
Income
—
Expenses
$200,000
Expense method
A: Lobbying Disclosure Act definitions
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
Deficit reduction/impact of sequestration on FDA and NIH
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNE ELIZABETH ESPOSITO | — |
Medical/Disease Research/Clinical Labs MED
Funding for rare disease research
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNE ELIZABETH ESPOSITO | — |
Medicare/Medicaid MMM
Non-interference; rebates; Protecting Seniors' Access to Medicare Act of 2013 (S 351 and HR 351)
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNE ELIZABETH ESPOSITO | — |
Manufacturing MAN
Pharmaceutical pedigree anti-counterfeiting proposals (S959 and HR 1919)
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNE ELIZABETH ESPOSITO | — |
Health Issues HCR
340B Drug Pricing Program; Critical Care; Pandemic and All-Hazards Preparedness Reauthorization Act of 2013 (HR 307)
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNE ELIZABETH ESPOSITO | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.